Recent research has identified PAD4 as a promising target for tumor therapy, with some studies indicating that highly tumor-targeted PAD4 inhibitors, modified with phenylbutyric acid (PBA), can inhibit tumors in vivo by specifically disrupting the PAD4-H3cit-NETs pathway in neutrophils [55]. This evidence concerns the gene PADI4 and neoplasm.